Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

Launched by LION TCR PTE. LTD. · Jan 4, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for advanced liver cancer related to hepatitis B virus (HBV). Specifically, it looks at a type of immune cell therapy called HBV-TCR T cells (LioCyx-M), which are specially trained to attack cancer cells, either on their own or combined with another medicine called lenvatinib. The goal is to see if this treatment is safe and effective for patients who have not had success with previous therapies for their liver cancer.

To join the study, participants should be adults aged 18 or older with advanced liver cancer that cannot be treated with surgery or other local therapies. They must also have a specific type of hepatitis B infection and be in reasonably good health. Participants can expect to receive the new treatment and will be closely monitored for safety and effectiveness throughout the trial. It’s important to note that those with certain health conditions, like severe heart disease or other active cancers, may not be eligible. This study is currently not recruiting participants, but it aims to find a potentially promising new option for patients facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
• • 2. Advanced HCC with diagnosis confirmed by histology/ cytology or clinically by AASLD criteria in cirrhotic patients.
• • 3. Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies
• • 4. Patients who failed first-line systemic therapy for HCC
• • 5. Serum HBsAg positivity
• • 6. Non-cirrhotic or compensated cirrhosis Child-Pugh A (5 - 6 points)
• • 7. HLA class 1 profile matching HLA-class I restriction element of the available T cell receptor
• Exclusion Criteria:
• • 1. Brain metastasis
• • 2. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment, except for in situ carcinoma of the cervix, non-melanoma skin carcinoma localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer and superficial bladder tumours.
• • 3. Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples
• • 4. History of severe allergic anaphylactic reactions to T cell therapy products and/or lenvatinib
• • 5. Local or loco-regional therapy of intrahepatic tumour lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks before the first infusion of LioCyx-M.
• • 6. Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, tyrosine kinase inhibitor therapy, and immunotherapy.
• • 7. Treatment with anticancer therapy, including investigational therapy, within 2 weeks prior to first infusion. For prior therapies with a half-life longer than 3 days, discontinuation of the therapy must have occurred at least 28 days prior to leukapheresis.
• • 8. Treatment with other investigational therapy within 28 days prior to initiation of study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.
• • 9. Likelihood to require any immunosuppressive treatments during the period of the clinical trial (Localized steroid use should be allowed)
• • 10. Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for HBV)
• • 11. Significant cardiovascular disease (such as New York Heart Association (NYHA) Functional Classification Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina
• • 12. Uncontrolled hypertension, defined as systolic blood pressure \>160 mmHg or diastolic pressure \>110 mmHg, despite optimal medical management